Dividend stocks are everywhere, but many just downright stink. In some cases, the business model is in serious jeopardy, or the dividend itself isn't sustainable. In others, the dividend is so low, it's not even worth the paper your dividend check is printed on. A�solid dividend�strikes the right balance of growth, value, and sustainability.
Today, and one day each week for the rest of the year, we're going to look at one dividend-paying company that you can put in your portfolio for the long term without too much concern. This isn't to say that these stocks don't share the same macro risks that other companies have, but they are a step above your common grade of dividend stock. Check out�last week's selection.
This week, I'll turn our attention to the auto sector and point out why it's time to forgive and forget by embracing Ford (NYSE: F ) as a prime dividend paying company.
Running out of gas?
It isn't hard to be skeptical of automakers, as many darn near fell of the face of the earth during the 2009 recession. General Motors (NYSE: GM ) , for instance, was forced to take a $49.5 billion loan from the government during its bankruptcy reorganization just so it could continue its day-to-day operations. Ford, while not having to stoop to the level of receiving government money, did ax its dividend for a period of five years, only reinstituting it last year.
Top 10 High Tech Companies For 2015: Cyberonics Inc (CYBX)
Cyberonics, Inc. (Cyberonics), incorporated in 1987, is a medical device company. The Company is engaged in the design, development, sales and marketing of implantable medical devices that provide a neuromodulation therapy, vagus nerve stimulation therapy (VNS Therapy), for the treatment of refractory epilepsy and treatment-resistant depression (TRD) and other device solutions for the management of epilepsy.VNS Therapy System includes an implantable pulse generator to provide stimulation to the vagus nerve; a lead that connects the generator to the vagus nerve; equipment to assist with implantation surgery; equipment to assist with setting the stimulation parameters for each patient; instruction manuals, and magnets to suspend or induce stimulation manually. The VNS Therapy pulse generator and lead are surgically implanted into patients generally during an outpatient procedure. The VNS Therapy System consists of a pulse generator, a bipolar lead, a programming wand and software and a tunneling tool.
The United States Food and Drug Administration (FDA) approved the Company's VNS Therapy System in July 1997 for use as an adjunctive therapy in epilepsy patients over 12 years of age for reducing the frequency of partial onset seizures that are refractory or resistant to antiepileptic drugs. Regulatory bodies in Canada, the European Economic Area, certain countries in Eastern Europe, Russia, South America, Africa, Australia and certain countries in Asia, including Japan, China and Taiwan, have approved the VNS Therapy System for the treatment of epilepsy, many without age restrictions or seizure-type limitations. In July 2005, the FDA approved the Company's VNS Therapy System for the adjunctive long-term treatment of chronic or recurrent depression for patients 18 years of age or older who are experiencing a depressive episode and have not had an adequate response to four or more adequate anti-depressant treatments. Regulatory bodies in the European Economic Area, Canada and Israel have approv! ed the Company's VNS Therapy System for the treatment of chronic or recurrent depression in patients who are in a treatment-resistant or treatment-intolerant depressive episode without age restrictions.
In February 2011, the Company announced FDA approval of its fifth generation generator, the AspireHC generator. In August 2011, the Company announced that the Company discovered a hardware-related design issue with the AspireHC Model 105 and AspireSR (Seizure Response) Model 106 generators. In December 2011, the FDA approved the Company's re-designed AspireHC generator, and the Company resumed its limited commercial release of the generator in the United States.
Pulse Generator
The pulse generator is an implantable, programmable signal generator designed to be coupled with the bipolar lead to deliver mild electrical pulses to the vagus nerve. The pulse generator is a battery-powered device. Before or upon depletion of the battery, the pulse generator may be removed and a new generator implanted in a short, outpatient procedure. The Model 102 (Pulse), Model 102R (Pulse Duo ), Model 103 (Demipulse), Model 104 (Demipulse Duo) and Model 105 (AspireHC), are the VNS Therapy pulse generators the Company offers and are similar in design and manufactures to a cardiac pacemaker.
Bipolar Lead
The bipolar lead conducts the electrical signal from the pulse generator to the vagus nerve. The lead incorporates electrodes, which are self-sizing, minimizing mechanical trauma to the nerve. The lead's two electrodes and anchor tether wrap around the vagus nerve, and the connector end is tunneled subcutaneously to the upper chest area, where it attaches to the pulse generator. The Company offers three lead models in the United States. The leads are available in two inner spiral diameter sizes to ensure optimal electrode placement on different-sized nerves.
Programming Wand and Software
The Company's programming wand and software are us! ed to int! errogate the implanted pulse generator and to transmit programming information from a handheld computer to the pulse generator via an inductive coupling. Programming capabilities include modification of the pulse generator's programmable parameters (pulse width, amplitude and frequency and stimulation ON and OFF intervals) and storage and retrieval of telemetry data.
Tunneling Tool
The tunneling tool is a single use, sterile, disposable surgical tool designed to be used during surgical placement of the bipolar lead. The tool is used for subcutaneous tunneling of the lead between the nerve site in the neck and the pulse generator site in the upper chest area.
Accessory Pack
The accessory pack includes two resistor assemblies used to test the function of the device prior to implantation, the bipolar lead tie-downs and one hex screwdriver. The patient kit includes two magnets, one watch-style and one pager-style.
The Company competes with Medtronic, Inc., NeuroSigma Inc. and CerboMed GmbH.
Advisors' Opinion:- [By Roberto Pedone]
Another potential earnings short-squeeze candidate is implantable medical devices player Cyberonics (CYBX), which is set to release numbers on Thursday after the market close. Wall Street analysts, on average, expect Cyberonics to report revenue of $74.05 million on earnings of 55 cents per share.
Read More: 5 Breakout Stocks Under $10 Set to Soar
The current short interest as a percentage of the float for Cyberonics is rather high at 11.6%. That means that out of the 21.65 million shares in the tradable float, 2.52 million shares are sold short by the bears. The bears have also been increasing their bets from the last reporting period by 4%, or by about 97,000 shares. If the bears get caught pressing their bets into a strong quarter, then shares of CYBX could easily rip sharply higher post-earnings as the shorts rush to cover some of their trades.
From a technical perspective, CYBX is currently trending above its 50-day moving average and just below its 200-day moving average, which is neutral trendwise. This stock recently formed a double bottom chart pattern at $55.75 to $56.56 a share. Following that bottom, shares of CYBX have started to trend back above its 50-day moving average of $59.83 a share and it's quickly moving within range of triggering a near-term breakout trade above some key overhead resistance levels.
If you're bullish on CYBX, then I would wait until after its report and look for long-biased trades if this stock manages to break out above some near-term overhead resistance levels at $63.65 to $64.08 a share with high volume. Look for volume on that move that hits near or above its three-month average action of 228,522 shares. If that breakout materializes post-earnings, then CYBX will set up to re-test or possibly take out its next major overhead resistance levels at $67.12 to $69.18 a share, or even $72 to its 52-week high at $73.52 a share.
I would avoid CYBX or look for short-biased trades if after earnin
- [By Benjamin Shepherd]
The rise of public health services, improvements in sanitation and access to clean drinking water have led to a huge improvement in human life expectancy, which has jumped from only about 30 years five centuries ago to more than 75 years in most industrialized countries today.
Advances in medical science have also played a major role, such as the development of antibiotics to treat once deadly infections, surgical interventions to correct once fatal injuries and medications to treat chronic conditions.
We have yet to reach the limit of human ingenuity and today the trend is towards harnessing technology to break the reliance on long-term medication usage to treat chronic conditions. One area where huge strides are being made in that direction is the treatment of epilepsy.
Epilepsy is the fourth most common neurological disease in the world, affecting more than 9 million people in developed countries alone, and epileptics have a mortality rate more than 25 times higher than the general population. The costs associated with dealing with the disease run in excess of $13.5 billion in the US alone.
The disease is typically treated using a drug regime that includes several pills a day, including anti-convulsants and sedatives which can have unpleasant side effects. Drug therapy is typically successful in controlling seizures in about 70 percent of patients, but about a third of those who don�� respond to medication find themselves undergoing surgery to essentially remove the area of the brain triggering the seizures.
Cyberonics (NSDQ: CYBX) is making headway into an alternative treatment for the disease, called vagus nerve stimulation (VNS) therapy, which can reduce the number or even eliminate the need for the drugs epileptics depend upon and requires only minor surgery.
During an outpatient procedure conducted under general anesthesia, two small incisions are made, one in the upper chest area and the other in the neck. At t - [By James E. Brumley]
Investors who were hoping things would work out for epilepsy treatment company Cyberonics, Inc. (NASDAQ:CYBX) can cross CYBX off their list of epilepsy-oriented stocks to buy, as they did with Acorda Therapeutics Inc. (NASDAQ:ACOR) about a month ago. ACOR saw its epilepsy drug Plumiaz rejected by the FDA in early May, while CYBX announced this morning that the coming fiscal year's (beginning in April) revenue would be weaker than first expected as sales of its epileptic control implant device didn't look quite as promising as hoped.
- [By Seth Jayson]
Calling all cash flows
When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on Cyberonics (Nasdaq: CYBX ) , whose recent revenue and earnings are plotted below.
Top 10 Heal Care Stocks To Invest In 2014: Transcept Pharmaceuticals Inc.(TSPT)
Transcept Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of proprietary products that address therapeutic needs in the field of neuroscience. Its principal product is the Intermezzo, a low dose sublingual formulation of zolpidem as a sleep aid for use in the middle of the night at the time a patient awakens and has difficulty returning to sleep. The company has a collaboration agreement with Purdue Pharmaceutical Products, L.P. for the commercialization of Intermezzo in the United States. It is also developing TO-2061, a low dose ondansetron adjunctive therapy, which is in Phase II study for patients with obsessive-compulsive disorder. The company was founded in 2002 and is based in Point Richmond, California.
Advisors' Opinion:- [By Roberto Pedone]
Transcept Pharmaceuticals (TSPT) is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in neuroscience. This stock closed up 6% to $2.98 in Thursday's trading session.
Thursday's Range: $2.81-$2.99
52-Week Range: $2.77-$6.77
Thursday's Volume: 138,000
Three-Month Average Volume: 158,095From a technical perspective, TSPT spiked sharply higher here right above some near-term support at $2.77 and back above its 50-day moving average at $2.95 with decent upside volume. This move is quickly pushing shares of TSPT within range of triggering a major breakout trade. That trade will hit if TSPT manages to take out some near-term overhead resistance levels at $3.16 to $3.25 with high volume. If that breakout hits, it would also push TSPT outside of a large consolidation pattern the stock has been in for the last three months.
Traders should now look for long-biased trades in TSPT as long as it's trending above some key near-term support at $2.77 and then once it sustains a move or close above those breakout levels with volume that hits near or above 158,095 shares. If that breakout triggers soon, then TSPT will set up to re-test or possibly take out its next major overhead resistance levels at $4.23 to its 200-day moving average at $4.50. Any high-volume move above those levels will then put $4.89 to $5 into range for shares of TSPT.
- [By Roberto Pedone]
An under-$10 biotech stock that's trending very close to triggering a near-term breakout trade is Transcept Pharmaceuticals (TSPT), which is focused on the development and commercialization of proprietary products that address important therapeutic needs in neuroscience. This stock has been hit hard by the bears so far in 2013, with shares off by 36%.
If you take a look at the chart for TSPT, you'll notice that this stock has been trending sideways inside of a big consolidation pattern for the last three months, with shares moving between $2.71 on the downside and $3.25 on the upside. Shares of TSPT are counter-trending higher today in the face of a very weak tape. This move is starting to push the stock within range of triggering a near-term breakout trade above the upper-end of its sideways trading chart pattern.
Traders should now look for long-biased trades in TSPT if it manages to break out above its 50-day moving average at $2.91 a share and then once it takes out more near-term overhead resistance levels at $3.16 to $3.25 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 138,444 shares. If that breakout triggers soon, then TSPT will set up to re-test or possibly take out its next major overhead resistance levels at $4.23 to its 200-day at $4.39 a share. If those levels get taken out with volume, then TSPT could easily hit its next major overhead resistance levels at $5 to $5.50 a share.
Traders can look to buy TSPT off weakness to anticipate that breakout and simply use a stop that sits right below its recent low of $2.71 a share. One can also buy TSPT off strength once it clears those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.
Top 10 Heal Care Stocks To Invest In 2014: Clear Channel Outdoor Holdings Inc (CCO)
Clear Channel Outdoor Holdings, Inc., incorporated in August 1995, provides clients with advertising opportunities through billboards, street furniture displays, transit displays and other out-of-home advertising displays, such as wallscapes, spectaculars, neons and mall displays, which it owns or operates in global markets. As of December 31, 2011, the Company owned or operated more than 750,000 advertising displays globally. During the year ended December 31, 2011, the Company operated in two business segments: Americas outdoor advertising (Americas) and International outdoor advertising (International), which represented 44% and 56% of its revenue, respectively.
Americas Outdoor Advertising
The Company is an outdoor advertising company in the Americas, which includes the United States, Canada and Latin America. As of December 31, 2011, the Company owned or operated approximately 125,000 display structures in its Americas segment with operations in 48 markets in the United States. Its Americas assets consist of billboards, street furniture and transit displays, airport displays, mall displays, and wallscapes and other spectaculars, which it owns or operates under lease management agreements.
Americas revenue is derived from the sale of advertising copy placed on its digital displays and its traditional displays. Its display inventory consists of billboards, street furniture displays and transit displays. During 2011, billboards consisted approximately 66% of its display revenues. Its Americas segment generates revenues from local, regional and national sales. Its billboard inventory includes bulletins and posters. Digital bulletins display static messages, which resemble standard printed bulletins when viewed, but also allow advertisers to change messages throughout the course of a day. Our electronic displays are linked through centralized computer systems to instantaneously and simultaneously change advertising copy as needed.
The Company�� ! street furniture displays include advertising surfaces on bus shelters, information kiosks, freestanding units and other public structures, are available in both traditional and digital formats, and are located in metropolitan areas and along commuting routes. The Company owns the street furniture structures and are responsible for their construction and maintenance. Its transit displays are advertising surfaces on various types of vehicles or within transit systems, including on the interior and exterior sides of buses, trains, trams, and within the common areas of rail stations and airports, and are available in both traditional and digital formats. The balance of its display inventory consists of spectaculars, wallscapes and mall displays. Spectaculars are customized display structures, which often incorporate video, multidimensional lettering and figures, mechanical devices and moving parts and other embellishments to create special effects. Its spectaculars are located in Times Square in New York City, Dundas Square and the Gardiner Expressway in Toronto, Fashion Show Mall in Las Vegas, Miracle Mile Shops in Las Vegas and across from the Target Center in Minneapolis.
As of December 31, 2011, the Company owned or operated approximately 125,000 display structures in its Americas segment with operations in 48 markets in the United States. Its displays are located on owned land, leased land or land, for which it have acquired permanent easements. The Company owns the physical structures on which its clients��advertising copy is displayed.
The Company competes with CBS and Lamar Advertising Company.
International Outdoor Advertising
The Company�� International segment includes its operations in Asia, Australia and Europe. As of December 31, 2011, the Company owned or operated more than 630,000 displays across 30 countries. Its International assets consist of street furniture and transit displays, billboards, mall displays, Smartbike schemes, walls! capes and! other spectaculars, which it owns or operates under lease agreements.
International revenue is derived from the sale of traditional advertising copy placed on its display inventory and electronic displays which are part of its network of digital displays. Its International display inventory consists of street furniture displays, billboards, transit displays and other out-of-home advertising displays, such as neon displays. Its International segment generates revenues globally from local, regional and national sales. Its International street furniture displays, available in traditional and digital formats, include bus shelters, freestanding units, various types of kiosks, benches and other public structures. Its International street furniture is sold to clients as network packages of multiple street furniture displays, with contract terms ranging from one to two weeks. Client contracts are also available with terms of up to one year.
The Company�� International billboards are sold to clients as network packages with contract terms ranging from one to two weeks. Long-term client contracts are also available and typically have terms of up to one year. It leases its billboard sites from private landowners. Billboards include posters and its neon displays, and are available in traditional and digital formats. Defi Group SAS, its International neon subsidiary, is a global provider of neon signs with approximately 296 displays in 16 countries globally.
The Company�� client contracts for transit displays, either traditional or digital, have terms ranging from one week to one year, or longer. The balance of its revenue from its International segment consists of advertising revenue from mall displays, other small displays and non-advertising revenue from sales of street furniture equipment, cleaning and maintenance services and production revenue. Its contracts with mall operators have terms ranging from 5 to 10 years and client contracts for mall displays generally ha! ve terms ! ranging from one to two weeks. Its International inventory includes other small displays, which are counted as separate displays. It also has a Smartbike bicycle rental program, which provides bicycles for rent to the general public in several municipalities. In exchange for providing the bike rental program, it derives revenue from advertising rights to the bikes, bike stations, additional street furniture displays, or fees from the local municipalities. It sells equipment or provides cleaning and maintenance services as part of a billboard or street furniture contract with a municipality. As of December 31, 2011, the Company owned or operated more than 630,000 displays in its International segment, with operations across 30 countries. Its International display count includes display faces, which may include multiple faces on a single structure.
The Company competes with JCDecaux and CBS.
Advisors' Opinion:- [By Seth Jayson]
Calling all cash flows
When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on Clear Channel Outdoor Holdings (NYSE: CCO ) , whose recent revenue and earnings are plotted below. - [By Paul Hodgson]
Clear Channel Outdoor Holdings (NYSE: CCO ) has just renewed CEO Robert Pittman's employment agreement. And that in itself is a little odd. The company's share price has shown no real net gain at all since his appointment in October 2011, but perhaps it's early days.
Top 10 Heal Care Stocks To Invest In 2014: MicroChannel Technologies Corp (MCTC)
MicroChannel Technologies Corporation, incorporated on February 28, 2005, is a development-stage company. The Company is focused on the identification, acquisition, and development of new and potentially commercial opportunities.
As of August 31, 2013, the Company is not engaged in any business operations. As of August 31, 2013, the Company had no revenues.
Advisors' Opinion:- [By Peter Graham]
Small cap stocks Bonamour Inc (OTCBB: BONI), Firstin Wireless Technology Inc (OTCMKTS: FINW) and Microchannel Technologies Corp (OTCBB: MCTC) have been attracting attention from variosu investment newsletters lately with at least two of these stocks being the subject of paid promotions. Of course, there is nothing wrong with properly disclosed paid promotions or investor relation types of activities as its up to investors and traders alike to do their due diligence. So how hot are these small cap stocks? Here is a quick reality check that might cool your appetite:
Top 10 Heal Care Stocks To Invest In 2014: CDI Corporation(CDI)
CDI Corp. provides engineering and information technology project outsourcing solutions and professional staffing services primarily in the United States, the United Kingdom, and Canada. It operates in four segments: ES, MRI, Anders, and ITS. The ES segment provides engineering, design, project management, staffing, and outsourcing solutions to oil, gas, refining, alternative energy, power generation and energy transmission, chemicals, and heavy manufacturing industries; engineering, design, logistics, and staffing services to the defense industry, primarily in marine design, systems development, and military aviation support; engineering, design, project management, staffing, and facility start-up services to pharmaceutical, bio-pharmaceutical, and regulated medical services industries; and architecture, civil and environmental engineering, communication technology, and consulting services to governmental, educational, and private industry customers. The MRI segment opera tes as a global franchisor that does business as MRINetwork and provides the use of its trademarks, business systems, and training and support services to its franchisees who engage in the search and recruitment of executive, technical, professional, and managerial personnel for employment by their customers. It also provides training, implementation services, and back-office services to enable franchisees to pursue staffing opportunities. The Anders segment provides contract and permanent placement candidates to customers in the areas of architecture, building services, rail, commercial and industrial construction, consulting engineering, facilities management, interior design, surveying, and town planning. The ITS segment offers various information technology related services, which include staffing augmentation, permanent placement, outsourcing, and consulting. The company was founded in 1950 and is based in Philadelphia, Pennsylvania.
Advisors' Opinion:- [By Rich Smith]
Philadelphia-based CDI Corp. (NYSE: CDI ) has won a $36 million contract to provide watercraft engineering and marine services to the U.S. Navy.
- [By Seth Jayson]
Calling all cash flows
When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on CDI (NYSE: CDI ) , whose recent revenue and earnings are plotted below.
Top 10 Heal Care Stocks To Invest In 2014: iShares 3-7 Year Treasury Bond ETF (IEI)
iShares Lehman 3-7 Year Treasury Bond Fund (the Fund) seeks investment results that correspond generally to the price and yield performance of the intermediate-term sector of the United States Treasury market as defined by the Lehman Brothers 3-7 Year U.S. Treasury Index (the Index). The Index includes all publicly issued the United States Treasury securities that have a remaining maturity of greater than or equal to three years and less than seven years, and have $250 million or more of outstanding face value. In addition, the securities must be denominated in United States dollars, and must be fixed-rate and non-convertible securities. Excluded from the Index are certain special issues, such as flower bonds, targeted investor notes, and state and local government series bonds, and coupon issues that have been stripped from assets that are already included in the Index.
The Index is a market capitalization-weighted index. The Fund invests in a representative sample of the securities in the Index, which has a similar investment profile as the Index. The Fund�� investment advisor is Barclays Global Fund Advisor.
Advisors' Opinion:- [By Donald van Deventer]
Shorter-duration Treasury Exchange-Traded Funds: (SHY), (SHV), (IEI), (BIL), (TUZ), (FIVZ), (DTUL), (VGSH), (DTUS), (DFVS), (DFVL), (SST), (ISTB), (TBZ).
Top 10 Heal Care Stocks To Invest In 2014: Great Northern Iron Ore Properties (GNI)
Great Northern Iron Ore Properties, a conventional nonvoting trust, owns and leases mineral and non-mineral properties on the Mesabi Iron Range in northeastern Minnesota. It owns mineral interests on the Mesabi Iron Range formation that represent 12,033 acres, including approximately 9,895 acres are under lease and 2,138 acres are unleased. The company was founded in 1906 and is based in Saint Paul, Minnesota.
Advisors' Opinion:- [By Aaron Levitt]
PrairieSky won�� actually be drilling for oil or natural gas on its properties, nor will it be transporting it through pipelines. That’s because a�royalty trust is an entity�that own the production rights on oil wells, natural gas fields or, as in the case of Great Northern Iron Ore Properties (GNI),�iron ore mines.
No comments:
Post a Comment